Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion. Click here to find out why PFE stock is a Buy.

Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition ...

GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a ...

Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY), two pharmaceutical giants, are excellent examples. These stocks aren ...

Pfizer Inc.'s strong Q2 2025 sales defy expectations. Discover analyst insights, growth drivers, and why it's rated Strong ...

Despite facing substantial headwinds, Pfizer's strategic pivot away from pandemic-related products is showing early signs of success. The company's second-quarter 2025 results revealed a 10% year-over ...

The advancement of Pfizer’s antibody-drug conjugate portfolio has not spared the former Seagen site—and those who helped develop the therapies—from layoffs. Pfizer is laying off 100 employees in ...

Respiratory syncytial virus (RSV) vaccination packed a protective punch that lasted beyond a single season and extended to ...

Two new real-world studies estimate the effectiveness of a single dose of a respiratory syncytial virus (RSV) vaccine against ...

Pfizer laid off 100 employees in Bothell, Wash., according to a filing with the state Employment Security Department posted on Monday. The pharmaceutical giant established a significant presence in ...

Pfizer permanently laid off 100 employees at the former Seagen campus in Bothell on Monday, according to a notice filed with the state’s Employment Security Department. A Pfizer spokesperson said ...